SALT LAKE CITY, May 23, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced seven new commercial coverage decisions for Prolaris ...
A series of class actions over the exclusion of coverage for GLP-1 weight loss drugs is testing several legal strategies ...
In recent years, the integration of artificial intelligence (AI) into various sectors has been nothing short of revolutionary. One such sector experiencing transformative change is health insurance, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback